Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutationJohn P. Clancy, Michael W. Konstan, Raouf Amin et al.|Thorax|2011Cited by 496
Efficacy of Aerosolized Tobramycin in Patients with Cystic FibrosisBonnie W. Ramsey, Arnold L. Smith, Henry L. Dorkin et al.|New England Journal of Medicine|1993Cited by 455